Equillium (0A4D) Stock Overview
A clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
0A4D Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Equillium, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.68 |
| 52 Week High | US$2.68 |
| 52 Week Low | US$0.28 |
| Beta | 1.67 |
| 1 Month Change | 30.41% |
| 3 Month Change | 48.89% |
| 1 Year Change | 596.10% |
| 3 Year Change | 327.20% |
| 5 Year Change | -58.83% |
| Change since IPO | -51.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A4D | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 27.6% | 1.3% | 0.9% |
| 1Y | 596.1% | 23.8% | 19.8% |
Return vs Industry: 0A4D exceeded the UK Biotechs industry which returned 23.8% over the past year.
Return vs Market: 0A4D exceeded the UK Market which returned 19.8% over the past year.
Price Volatility
| 0A4D volatility | |
|---|---|
| 0A4D Average Weekly Movement | 15.3% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in GB Market | 12.0% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: 0A4D's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A4D's weekly volatility has decreased from 24% to 15% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 15 | Bruce Steel | www.equilliumbio.com |
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases.
Equillium, Inc. Fundamentals Summary
| 0A4D fundamental statistics | |
|---|---|
| Market cap | US$166.29m |
| Earnings (TTM) | -US$19.05m |
| Revenue (TTM) | n/a |
Is 0A4D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A4D income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$19.06m |
| Earnings | -US$19.05m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0A4D perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/28 16:03 |
| End of Day Share Price | 2026/05/27 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Equillium, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Wood | B. Riley Securities, Inc. |
| Steven Seedhouse | Cantor Fitzgerald & Co. |
| Roger Song | Jefferies LLC |